ATE207359T1 - Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin - Google Patents

Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin

Info

Publication number
ATE207359T1
ATE207359T1 AT96930553T AT96930553T ATE207359T1 AT E207359 T1 ATE207359 T1 AT E207359T1 AT 96930553 T AT96930553 T AT 96930553T AT 96930553 T AT96930553 T AT 96930553T AT E207359 T1 ATE207359 T1 AT E207359T1
Authority
AT
Austria
Prior art keywords
temozolomide
cisplatin
advanced cancer
combination therapy
treating
Prior art date
Application number
AT96930553T
Other languages
English (en)
Inventor
Margaret H Dugan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE207359T1 publication Critical patent/ATE207359T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT96930553T 1995-08-28 1996-08-26 Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin ATE207359T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US287795P 1995-08-28 1995-08-28
US62479596A 1996-03-27 1996-03-27
PCT/US1996/013479 WO1997007804A1 (en) 1995-08-28 1996-08-26 Combination therapy for advanced cancer comprising temozolomide and cisplatin

Publications (1)

Publication Number Publication Date
ATE207359T1 true ATE207359T1 (de) 2001-11-15

Family

ID=26670993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96930553T ATE207359T1 (de) 1995-08-28 1996-08-26 Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin

Country Status (11)

Country Link
EP (1) EP0858341B1 (de)
JP (1) JPH10511108A (de)
AT (1) ATE207359T1 (de)
AU (1) AU6955396A (de)
CA (1) CA2229141A1 (de)
DE (1) DE69616367T2 (de)
DK (1) DK0858341T3 (de)
ES (1) ES2162092T3 (de)
GR (1) GR3037047T3 (de)
PT (1) PT858341E (de)
WO (1) WO1997007804A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251850B1 (de) * 2000-01-26 2006-06-21 Schering Corporation Kombinationspräparat zur krebstherapie
WO2007084532A2 (en) * 2006-01-17 2007-07-26 Abbott Laboratories Combination therapy with parp inhibitors
HUE028908T2 (en) 2006-04-05 2017-01-30 Opko Health Inc The hydrochloride salt of 8 - [{1- (3,5-bis (trifluoromethyl) phenyl) ethoxy} methyl] -8-phenyl-1,7-diazaspiro [4.5] decan-2-one, and process
WO2007114921A2 (en) 2006-04-05 2007-10-11 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one and treatment methods using the same
EP2379080A1 (de) * 2009-01-13 2011-10-26 ProteoSys AG Pirenzepin als otoprotektives mittel
AU2021207599A1 (en) 2020-01-13 2022-08-04 Memorial Sloan Kettering Cancer Center Methods and compositions for cancer immunotherapy

Also Published As

Publication number Publication date
GR3037047T3 (en) 2002-01-31
DK0858341T3 (da) 2001-11-19
EP0858341B1 (de) 2001-10-24
JPH10511108A (ja) 1998-10-27
MX9801585A (es) 1998-05-31
DE69616367T2 (de) 2002-06-27
WO1997007804A1 (en) 1997-03-06
ES2162092T3 (es) 2001-12-16
AU6955396A (en) 1997-03-19
PT858341E (pt) 2002-03-28
DE69616367D1 (de) 2001-11-29
EP0858341A1 (de) 1998-08-19
CA2229141A1 (en) 1997-03-06

Similar Documents

Publication Publication Date Title
GEP20002146B (en) Therapeutic Peptide Derivatives
PT880350E (pt) Tratamento de esclerose multipla
DE69532961D1 (de) Verwendung von porphyrine in der behandlung von multiple sklerose
ATE232082T1 (de) Prophylaktische und therapeutische behandlung von haupt sensibilisierung und -reizung
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
CY1105564T1 (el) Θεραπεια συνδυασμου για καρκινο
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
ATE207359T1 (de) Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin
PT859630E (pt) Combinacao de temozolomida e alfa-ifn no tratamento de cancro avancado
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
DE69821970D1 (de) Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
MX9603833A (es) Tratamiento mejorado del cancer con temozolomida.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
RU94024337A (ru) Антиметастатическое средство
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
WO2000033823A3 (en) Methods of using temozolomide in the treatment of cancers
SU1823193A1 (ru) Способ лечения рака гортани
DE59506911D1 (de) Verwendung von intravenös applizierbarem eisen zur therapie von tumorerkrankungen und/oder infektionskrankheiten
UA23985A (uk) Спосіб лікуваhhя запальhих захворюваhь вhутрішhіх геhіталій у дівчат та підлітків
RU94020918A (ru) Способ лечения опсоменореи
ES8705241A2 (es) Procedimiento de terapia por campos magneticos con multipli-cidad de tipos de onda y control de solenoide bajo procesa- dor
UA30257A (uk) Спосіб нормалізації тканинного обміну та відновлення морфофункціонального стану органів і тканин
UA30126A (uk) Спосіб лікування пізнього гестозу вагітних

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee